Want to see SE:SPEC full AI Analyst Report?
Top Page
SpectraCure AB
(SPEC)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.06
▼(-66.67% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily held down by very weak operating fundamentals—negligible revenue, sizable ongoing losses, and continued negative operating/free cash flow. Technicals add further pressure as the stock trades below all major moving averages, signaling a persistent downtrend. The main stabilizer is a low-leverage balance sheet, but it does not offset the current lack of commercial scale and cash burn.
Positive Factors
Low leverage balance sheet
Very low leverage (debt/equity ~0.03) reduces near-term solvency risk and gives management runway to fund clinical development. For a precommercial medtech, low debt preserves optionality for staged financing, partnerships, and execution over several quarters.
Negative Factors
Negligible revenue
Reported revenue is effectively zero, indicating no commercial sales traction. Without operational revenue, the company remains wholly dependent on financing to fund development and overhead, limiting ability to validate the business model or scale operations over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
Very low leverage (debt/equity ~0.03) reduces near-term solvency risk and gives management runway to fund clinical development. For a precommercial medtech, low debt preserves optionality for staged financing, partnerships, and execution over several quarters.
Read all positive factors
SpectraCure AB (SPEC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr36.40M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)-0.05
Revenue GrowthN/A
EPS Growth-85.81%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.19
Shares Outstanding570,602,840
10 Day Avg. Volume1,242,664
30 Day Avg. Volume1,152,681
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SpectraCure AB Business Overview & Revenue Model
Company Description
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT)...
How the Company Makes Money
null...
SpectraCure AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 318.00K | 539.00K | 0.00 |
| Gross Profit | -27.03M | -30.14M | 9.77M | -9.22M | 3.58M | 1.39M |
| EBITDA | -24.81M | -24.22M | -20.42M | -20.97M | -22.27M | -20.43M |
| Net Income | -55.90M | -56.08M | -23.00M | -20.44M | -25.33M | -23.34M |
Balance Sheet | ||||||
| Total Assets | 111.01M | 104.47M | 121.00M | 144.83M | 162.42M | 190.52M |
| Cash, Cash Equivalents and Short-Term Investments | 16.59M | 13.53M | 18.27M | 56.95M | 93.18M | 129.69M |
| Total Debt | 2.19M | 3.01M | 5.14M | 6.72M | 2.70M | 4.90M |
| Total Liabilities | 10.60M | 10.92M | 14.15M | 14.97M | 12.12M | 14.84M |
| Stockholders Equity | 100.41M | 93.55M | 106.86M | 129.86M | 150.30M | 175.68M |
Cash Flow | ||||||
| Free Cash Flow | -28.61M | -43.67M | -37.10M | -34.45M | -33.08M | -27.09M |
| Operating Cash Flow | -23.75M | -24.03M | -21.83M | -18.68M | -22.96M | -18.60M |
| Investing Cash Flow | -20.22M | -19.64M | -15.28M | -15.56M | -11.35M | -8.49M |
| Financing Cash Flow | 52.47M | 38.92M | -1.57M | -1.99M | -2.20M | -453.00K |
SpectraCure AB Technical Analysis
Neutral
0.18
Price Trends
0.08
Negative
0.09
Negative
0.13
Negative
Market Momentum
-0.01
Negative
45.13
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Neutral. The current price of 0.18 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.13 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SPEC.
SpectraCure AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr183.55M | -1.78 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr47.89M | -13.76 | ― | ― | -12.32% | -1156.14% | |
44 Neutral | kr345.62M | -1.60 | -253.54% | ― | 41.17% | 29.20% | |
43 Neutral | kr32.80M | -0.77 | -60.56% | ― | 27.31% | 6.31% | |
41 Neutral | kr36.40M | -0.34 | -50.21% | ― | ― | -85.81% |
* Healthcare Sector Average
SE:SPEC
SpectraCure AB
0.06
-0.18
-74.09%
SE:SCIB
SciBase Holding AB
33.50
2.25
7.20%
SE:LXB
Luxbright AB
0.13
-0.55
-81.36%
SE:HEART
Scandinavian Real Heart AB
20.60
6.95
50.90%
SE:SDOS
ScandiDos AB
0.83
-0.51
-38.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.